Letters, Testimony & Comments

April 11, 2006
A Panel from the BIO Annual Convention 2006.
April 6, 2006
Statement of Peter Young, President and CEO of AlphaVax, Inc. on Behalf of BIO, the Biotechnology Industry Organization Presented before the House Energy and Commerce Committee Subcommittee on Health April 6, 2006 Good afternoon and thank...
March 31, 2006
Letter to USTR on continuing concerns.
March 24, 2006
Comments to the USTR touching on Intellectual Property Rights, Biosafety Protocol Implementation, Adventitious Presence, and Labeling.
March 24, 2006
Comments to the USTR touching on Intellectual Property Rights, Biosafety Protocol Implementation, Adventitious Presence, and Labeling.
March 1, 2006
BIO's comments regarding the Medicare Prescription Drug, Improvement, and Modernization Act of 2003; Section 1013: Identification of Priority Topics for Effective Health Care Research
March 1, 2006
The Biotechnology Industry Organization (BIO) appreciates this opportunity to testify before the Advisory Panel on Ambulatory Payment Classifications (the APC Panel). BIO is the largest trade organization to serve and represent the biotechnology...
February 27, 2006
BIO's Comments on Authoritative Drug Compendia That May Be Used in Determining Medically Accepted Indications of Drugs and Biologicals Used in an Anti-Cancer Chemotherapeutic Regimen.
February 14, 2006
This morning at breakfast I noted that this year's conference is our most well-attended yet. In just the past few hours, the numbers have continued to grow. We now have 1684 participants registered and still counting - even in the midst of a record-...
February 7, 2006
Supporting the Genetic Information Nondiscrimination Act (GINA)
January 20, 2006
BIO's Comments on the Centers for Medicare and Medicaid Servicesí interim final rule regarding exclusion of vendor purchases made under the Competitive Acquisition Program (CAP) for outpatient drugs and biologicals under Part B.